Comparative Pharmacology
Head-to-head clinical analysis: XYREM versus XYWAV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XYREM versus XYWAV.
XYREM vs XYWAV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gamma-hydroxybutyrate (GHB) agonist at GABA-B and GHB receptors, modulating dopamine and serotonin activity.
XYWAV (calcium, magnesium, potassium, and sodium oxybates) is a mixture of oxybate salts. The exact mechanism of action is unknown, but it is thought to involve modulation of GABA-B receptors and possibly GHB receptors, leading to increased slow-wave sleep and reduced cataplexy.
9 g orally per night divided into two doses: first dose of 4.5 g at bedtime, second dose of 4.5 g given 2.5 to 4 hours later. Titrate based on efficacy and tolerability; range 6 to 9 g per night.
Oral, starting dose 2.25 g twice nightly, titrated weekly by 0.75 g per dose up to a maximum of 4.5 g twice nightly. Administer first dose at bedtime, second dose 2.5–4 hours later.
None Documented
None Documented
0.5–1 hour; clinical context: requires twice-nightly dosing for sustained effects in narcolepsy.
Terminal half-life is approximately 1 hour (range 0.5–1.5 hours) for oxybate (GHB) component; the mixed salts formulation does not alter elimination. Short half-life necessitates twice-nightly dosing for sustained sleep.
Primarily renal (≥95% as metabolites, mainly as CO2 and succinate via Krebs cycle); negligible biliary/fecal excretion.
Primarily renal; >95% of the dose is eliminated as metabolites (3-hydroxypropionic acid, 4,5-dihydroxyhexanoic acid) and <5% as unchanged drug via urine. Fecal excretion accounts for <1%.
Category C
Category C
CNS Depressant / Narcolepsy Agent
CNS Depressant / Narcolepsy Agent